Safety evaluation of M9241 in combination with docetaxel in metastatic prostate cancer.Mohammad Atiq, Ravi A. Madan, Charalampos S. Floudas et al.|Journal of Clinical Oncology|2022Cited by 4
Evaluating the optimal sequence of immunotherapy and docetaxel in men with metastatic castration-sensitive prostate cancer.Elias Bin Aris Chandran, Ravi A. Madan, Mohammad Atiq et al.|Journal of Clinical Oncology|2022Cited by 3
Combining IL-12 immunocytokine (M9241) with docetaxel in metastatic prostate cancer: A phase I study.Mohammad Atiq, Ravi A. Madan, Elias Bin Aris Chandran et al.|Journal of Clinical Oncology|2022Cited by 3
1614P PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)Ravi A. Madan, Fatima Karzai, Esther Mena Gonzalez et al.|Annals of Oncology|2024Cited by 2
PSMA PET findings in patients with undetectable PSA more than 3 years after docetaxel for metastatic castration-sensitive prostate cancer (mCSPC).Mohammad Atiq, Ravi A. Madan, Shruti U. Gandhy et al.|Journal of Clinical Oncology|2022Cited by 1